Researchers at Stanford University have identified a groundbreaking method to predict the longevity of vaccine-induced immunity using a specific blood test. The discovery, published in Nature Immunology, sheds light on why some vaccines, such as those for measles, provide lifelong protection, while others, like the influenza vaccine, require frequent updates and boosters. The study highlights the role of megakaryocytes, blood cells traditionally known for their role in clotting, in promoting long-lasting antibody responses.
A Decade-Old Mystery in Vaccine Science
Vaccines vary widely in how long their protective effects last. For instance, the measles-mumps-rubella (MMR) vaccine offers protection for decades, while immunity from a flu shot often wanes within months. This variability has puzzled scientists for years.
“The question of why some vaccines induce durable immunity while others do not has been one of the great mysteries in vaccine science,” said Dr. Bali Pulendran, senior author of the study and professor of microbiology and immunology at Stanford.
The research team uncovered a molecular signature in the blood that emerges within days of vaccination and predicts the durability of the immune response. This discovery is a significant advancement over prior studies, which could only predict early antibody responses, not their longevity.
Key Role of Megakaryocytes
The study zeroes in on megakaryocytes, large bone marrow cells that produce platelets. While platelets are essential for blood clotting, they also carry tiny pieces of RNA derived from megakaryocytes. These RNA fragments serve as indicators of megakaryocyte activity and, as the study revealed, correlate strongly with the durability of antibody responses to vaccines.
Using an experimental H5N1 bird flu vaccine with and without an adjuvant—a substance that enhances the immune response—the researchers followed 50 healthy volunteers over 100 days. Advanced machine-learning algorithms analysed the genetic, protein, and antibody data collected. The findings pointed to a specific molecular signature involving RNA from megakaryocytes that predicted long-term antibody production.
“What we learned was that the platelets are a bellwether for what is happening with megakaryocytes in the bone marrow,” Pulendran explained.
Experimental Confirmation
To validate their findings, researchers conducted experiments on mice, administering the bird flu vaccine alongside thrombopoietin, a drug that boosts megakaryocyte activity. The results were striking: antibody levels against the virus increased sixfold after two months. Further experiments revealed that megakaryocytes produce molecules that support the survival of plasma cells, which are responsible for antibody production.
“Our hypothesis is that megakaryocytes provide a nurturing, pro-survival environment in the bone marrow for plasma cells,” Pulendran said.
Broader Implications Across Vaccines
The researchers extended their findings to other vaccines, analysing data from 244 individuals who had received vaccines for influenza, yellow fever, malaria, and COVID-19, among others. In each case, the same platelet RNA signature correlated with long-lasting antibody responses.
The study offers a new perspective on why certain vaccines are more durable and highlights megakaryocytes as key players in vaccine effectiveness.
Toward Predictive and Personalised Vaccines
This discovery paves the way for significant advancements in vaccine development. The team is exploring why some vaccines trigger higher levels of megakaryocyte activation and how this knowledge can be used to design vaccines with longer-lasting effects.
In the short term, the researchers aim to develop a simple blood test, such as a PCR-based “vaccine chip,” to measure the molecular signature in patients shortly after vaccination. This tool could predict how long immunity will last, helping personalise vaccination schedules and streamlining clinical trials.
“We could identify who may need a booster and when,” Pulendran said. However, he cautioned that megakaryocytes are likely one part of a larger, complex system that influences vaccine durability.
Collaborative Effort
The study was a collaborative effort involving scientists from institutions including Emory University, the University of Cincinnati, the National Institutes of Health, and the Icahn School of Medicine. Contributors also included researchers from global organisations such as GSK Belgium and Hospital Israelita Albert Einstein.
By uncovering this crucial mechanism, the study marks a significant step toward understanding and improving vaccine durability, with potential implications for public health worldwide.
Read also:
Breakthrough Malaria Vaccine Shows Promising Results in Clinical Trial
